Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | Immunotherapy approaches in ALL

Josep-Maria Ribera • 19 Jun 2020
ESH AL 2020
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab CAR-T Inotuzumab ozogamicin

Josep-Maria Ribera, MD, PhD, Germans Trias i Pujol University Hospital, Barcelona, Spain, discusses the latest developments in newly diagnosed and relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) research. Specifically, Prof. Ribera explores evolving immunotherapy approaches and measurable residual disease (MRD) assessment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Josep-Maria Ribera

1:25
BURKIMAB14: dose reduction of chemotherapy in young adults with Burkitt lymphoma
Josep-Maria Ribera • 9 Jun 2023
0:55
PhALLCON: Phase III study of ponatinib vs imatinib in newly diagnosed Ph+ ALL
Josep-Maria Ribera • 9 Jun 2023
1:02
Incorporating immunotherapy into the first-line treatment of ALL
Josep-Maria Ribera • 9 Jun 2023
1:31
PETHEMA LAL19: continuation therapy or allogeneic transplantation according to MRD & genetics in ALL
Josep-Maria Ribera • 8 Oct 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals